



an Open Access Journal by MDPI

Novel Biomarkers and Therapeutic Discoveries for Cardiovascular Diseases

Guest Editor:

Assoc. Prof. Aaron Sverdlov

1. School of Medicine and Public Health, College of Health Medicine and Wellbeing, University of Newcastle, NSW, Australia

2. Cardiovascular Department, John Hunter Hospital, Hunter New England Local Health District, NSW, Australia

aaron.sverdlov@newcastle. edu.au

Assoc. Prof. Doan Ngo

1. School of Biomedical Sciences and Pharmacy, College of Health Medicine and Wellbeing, University of Newcastle, NSW, Australia

2. Hunter Medical Research Institute, NSW, Australia

Doan.Ngo@newcastle.edu.au

Deadline for manuscript submissions: **15 March 2022**

Message from the Guest Editor

Dear Colleagues,

Biomarkers are important tools to assist a clinician with diagnosis, prognosis, and/or screening for a variety of conditions, and also to assist with the clinical management of a patient. In the cardiovascular field, the prevention and early identification of disease states leads to early treatment with improved outcomes, patient satisfaction, reduced healthcare costs, morbidity, and mortality. The identification of early changes contributing to disease states and/or the identification of patients at risk, is typically achieved via a combination of good clinical skills and the availability of appropriate diagnostic modalities. The use of biomarkers provides a diagnostic modality that is typically easy to perform and/or inexpensive. For this Special Issue, entitled "Novel Biomarkers and Therapeutic Discoveries for Cardiovascular Diseases", we seek manuscripts related to the development, testing, and effectiveness of novel biomarkers in the field of cardiovascular disease, use of established biomarkers for new indications, and use of biomarkers to predict therapeutic responses across a variety of cardiovascular disease states



